Actively Recruiting
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Led by Beth Israel Deaconess Medical Center · Updated on 2026-03-13
35
Participants Needed
3
Research Sites
179 weeks
Total Duration
On this page
Sponsors
B
Beth Israel Deaconess Medical Center
Lead Sponsor
G
Genmab
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a type of antibody)
CONDITIONS
Official Title
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Biopsy-confirmed follicular lymphoma grade 1-3A that is CD20 positive at diagnosis
- Measurable disease with at least one lymph node ≥1.5 cm long axis and >1.0 cm short axis with Deauville score ≥4 on PET/CT
- Stage III or IV follicular lymphoma at initial diagnosis
- Received one prior line of systemic therapy including anti-CD20 antibody plus chemotherapy (at least 3 cycles)
- Achieved partial response or stable disease after upfront treatment, not progressive disease
- Completed prior anti-lymphoma therapy at least 4 weeks before starting epcoritamab
- Age 18 years or older
- ECOG performance status of 0 to 2
- Life expectancy greater than 2 years
- Adequate organ and marrow function as defined by blood counts and liver/kidney tests
- If hepatitis B core antibody positive on antiviral therapy with negative PCR, must receive antiviral prophylaxis
- Hepatitis C antibody positive with undetectable viral load
- Prior malignancy allowed if treated with curative intent at least 2 years prior and no current disease
- Resolved toxicities from prior therapy to baseline or grade 1 (except grade 2 peripheral neuropathy or any grade alopecia)
- Ability to understand and sign informed consent
- Agree to use highly effective birth control if of childbearing potential and follow contraception guidelines during and after study
You will not qualify if you...
- Use of investigational agents in prior induction therapy
- Uncontrolled active infection requiring hospitalization or IV antibiotics within 4 weeks prior to treatment
- Uncontrolled cardiac conditions including heart failure grade III/IV, low ejection fraction (<45%), unstable angina, recent myocardial infarction (<6 months), or arrhythmia
- History of uncontrolled neurological conditions such as seizures, stroke, psychosis, dementia, CNS vasculitis, or encephalitis
- Need for supplemental oxygen at rest to maintain adequate oxygen saturation
- Immunosuppressive therapy for non-lymphoma reasons within 28 days or lymphoma reasons within 10 days before treatment
- Known or suspected CNS involvement or leptomeningeal disease
- Pregnant or breastfeeding women or unwillingness to follow contraception guidelines
- Known current alcohol or drug abuse, psychiatric illness, or unstable social situation limiting study compliance
- History of allergic reactions to compounds similar to epcoritamab
- Exposure to live or live attenuated vaccines within 4 weeks
- HIV infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Stanford
Stanford, California, United States, 94305
Actively Recruiting
2
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Actively Recruiting
3
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Actively Recruiting
Research Team
G
Gottfried von Keudell, MD, PhD
CONTACT
D
Dea Hunsicker, MSN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here